This is a Phase 1 study during which patients with advanced cancer will receive
investigational study drug ARRY-382. Patients will receive increasing doses of study drug in
order to achieve the highest dose of the study drug possible that will not cause unacceptable
side effects. Patients will be followed to see what side effects and effectiveness the study
drug has, if any, in treating the cancer. Approximately 50 patients from the US will be
enrolled in this study.